(Sharecast News) - Danish pharma giant Novo Nordisk has narrowed and lowered its guidance range for sales growth this year as heightened competition from cheaper weight-loss treatments continues to dampen the outlook for its breakthrough Ozempic and Wegovy drugs.
The company now expects sales to increase by 8-11% at constant exchange...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE